PTEN status in advanced colorectal cancer treated with cetuximab

被引：64

作者：

Negri, F. V. ^{[1
]}

Bozzetti, C. ^{[1
]}

Lagrasta, C. A. ^{[2
]}

Crafa, P. ^{[2
]}

Bonasoni, M. P. ^{[3
]}

Camisa, R. ^{[1
]}

Pedrazzi, G. ^{[4
]}

Ardizzoni, A. ^{[1
]}

机构：

[1] Univ Hosp, Med Oncol Unit, I-43100 Parma, Italy

[2] Univ Hosp, Dept Pathol, Parma, Italy

[3] Arcispedale S Maria Nuova, Dept Pathol, Reggio Emilia, Italy

[4] Univ Parma, Dept Publ Hlth, Parma, Italy

来源：

BRITISH JOURNAL OF CANCER | 2010年 / 102卷 / 01期

关键词：

PTEN; colorectal cancer; cetuximab; GROWTH-FACTOR RECEPTOR; PLUS IRINOTECAN; EGFR; INHIBITORS; THERAPY; TUMORS; SHOWS;

D O I：

10.1038/sj.bjc.6605471

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND: Loss of phosphatase and tensin homologue deleted in chromosome 10 (PTEN) function in advanced colorectal cancer (CRC) may represent one of the resistance mechanisms to cetuximab by interfering with the epidermal growth factor receptor signal transduction pathway. METHODS: PTEN expression tested by indirect immunofluorescence was evaluated both on primary (n = 43) and on metastatic (n = 24) sites in CRC patients treated with cetuximab. RESULTS: The loss of PTEN expression tested on metastatic sites was negatively associated with response (100% progressive disease (PD) in PTEN-negative cases vs 30% PD in PTEN-positive cases; P<0.05), PFS (0.8 vs 8.2 months; P<0.001) and OS (2.9 vs 14.2 months; P<0.001). CONCLUSION: A potential role of PTEN in the anti-tumour activity of cetuximab could be hypothesised. British Journal of Cancer (2010) 102, 162-164. doi:10.1038/sj.bjc.6605471 www.bjcancer.com Published online 1 December 2009 (C) 2010 Cancer Research UK

引用

页码：162 / 164

页数：3

共 13 条

[1]

Baselga J, 2001, EUR J CANCER, V37, pS16

[2] Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors [J].

Bianco, R ;

Shin, I ;

Ritter, CA ;

Yakes, FM ;

Basso, A ;

Rosen, N ;

Tsurutani, J ;

Dennis, PA ;

Mills, GB ;

Arteaga, CL .

ONCOGENE, 2003, 22 (18) :2812-2822

[3] Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J].

Chung, KY ;

Shia, J ;

Kemeny, NE ;

Shah, M ;

Schwartz, GK ;

Tse, A ;

Hamilton, A ;

Pan, D ;

Schrag, D ;

Schwartz, L ;

Klimstra, DS ;

Fridman, D ;

Kelsen, DP ;

Saltz, LB .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1803-1810

[4] Drug therapy: EGFR antagonists in cancer treatment [J].

Ciardiello, Fortunato ;

Tortora, Giampaolo .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11) :1160-1174

[5] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[6] PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer [J].

Loupakis, Fotios ;

Pollina, Luca ;

Stasi, Irene ;

Ruzzo, Annamaria ;

Scartozzi, Mario ;

Santini, Daniele ;

Masi, Gianluca ;

Graziano, Francesco ;

Cremolini, Chiara ;

Rulli, Eliana ;

Canestrari, Emanuele ;

Funel, Niccola ;

Schiavon, Gaia ;

Petrini, Iacopo ;

Magnani, Mauro ;

Tonini, Giuseppe ;

Campani, Daniela ;

Floriani, Irene ;

Cascinu, Stefano ;

Falcone, Alfredo .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) :2622-2629

[7] Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant [J].

Molinari, F. ;

Martin, V. ;

Saletti, P. ;

De Dosso, S. ;

Spitale, A. ;

Camponovo, A. ;

Bordoni, A. ;

Crippa, S. ;

Mazzucchelli, L. ;

Frattini, M. .

BRITISH JOURNAL OF CANCER, 2009, 100 (07) :1087-1094

[8] Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study [J].

Moroni, M ;

Veronese, S ;

Benvenuti, S ;

Marrapese, G ;

Sartore-Bianchi, A ;

Di Nicolantonio, F ;

Gambacorta, M ;

Siena, S ;

Bardelli, A .

LANCET ONCOLOGY, 2005, 6 (05) :279-286

[9] Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor [J].

Saltz, LB ;

Meropol, NJ ;

Loehrer, PJ ;

Needle, MN ;

Kopit, J ;

Mayer, RJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1201-1208

[10] Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN [J].

Stambolic, V ;

Suzuki, A ;

de la Pompa, JL ;

Brothers, GM ;

Mirtsos, C ;

Sasaki, T ;

Ruland, J ;

Penninger, JM ;

Siderovski, DP ;

Mak, TW .

CELL, 1998, 95 (01) :29-39

← 1 2 →